Despite multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA)-ligand positron emission tomography/computed tomography (PET/CT) have revolutionised the diagnostic pathway of PCa, their role in preoperative staging, treatment planning, and in the PCa recurrence setting is less defined [5, 6]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.